Ronald Harold Wilfred Cooper - Jul 22, 2022 Form 4 Insider Report for ALBIREO PHARMA, INC. (ALBO)

Role
President and CEO, Director
Signature
/s/ Jason Duncan, Attorney-in-fact
Stock symbol
ALBO
Transactions as of
Jul 22, 2022
Transactions value $
-$22,923
Form type
4
Date filed
7/25/2022, 04:09 PM
Previous filing
Jun 13, 2022
Next filing
Jan 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Sale -$22.9K -929 -1.62% $24.67 56.4K Jul 22, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 Represents 25,942 shares of common stock and 30,438 restricted stock units. Includes 1,227 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2022.